What percentage of hits are biotechnology (macromolecules) origin?

• A. 10%
• B. 5%
• C. 50%
• D. 1%

Answer: (D)

Biotech-origin hits are a tiny minority in typical screening results. Standard high-throughput screening libraries are dominated by small molecules, which are well-suited to common assay formats, have favorable stability and cell permeability, and fit drug-like properties. Macromolecules from biotechnology—proteins, peptides, antibodies—pose more challenges: they’re larger, often require specialized assay setups, and their properties make them harder to work with in the usual screening workflows. Because of these differences, only a small fraction of hits come from biotech origins, so the most accurate view is that biotech macromolecule hits compose a very small portion of total hits.